PIPELINE.

Sterling Knight Pharmaceuticals has multiple projects in various stages of development.

Image of angled design element

Sterling Knight has an aggressive product development pipeline, including new drug applications “NDAs” through 505(b)(2) pathways, abbreviated new drug applications (“ANDAs”) and 510k medical devices.

With continued commitment to our core values, Sterling Knight intends to expand its product offering through the execution of its Research and Development initiatives. The company has numerous drugs in various stages of development.


Compound 1

MR-0601 (ANDA) oral

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

80%

Compound 2

MR-0722 (ANDA) oral

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

40%

Compound 3

MR-0342 (ANDA) oral

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

40%

Compound 4

AG-0154 (NDA) topical

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

40%

Compound 5

AN-0166 (NDA) topical

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

20%

Compound 6

NS-0232 (NDA) topical

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

20%

Compound 7

NS-0421 (NDA) topical

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

20%

Compound 8

NS-0154 (NDA) oral

Under Evaluation

In Development

Filed

FDA Approved

Commercialized

20%